Mabylon is a leading Swiss biotech company active in the field of therapeutic antibodies targeting crucial, disease-relevant epitopes for the treatment of neurodegenerative disorders, neuroinflammation, and allergies. Mabylon employs cutting edge antibody discovery technology as well as human antibody screens leveraging both targeted and large unbiased patient populations (screening tens of thousands of patients per target). Mabylon was spawned from the research of Prof. Adriano Aguzzi, renowned neuropathologist at the University and University Hospital of Zurich and has different assets at the preclinical stage for the treatment of allergies and neurological disorders, including Alzheimer's disease. In the neuroscience therapeutic area our lead antibody program for ALS/FTLD targets TDP-43, was identified by screening 60,000 patients, and has been partnered with SciNeuro Pharmaceuticals. In neuroinflammation we have developed a monoclonal antibody targeting ASC, a crucial component of the inflammasome, for the treatment of Alzheimer's disease. In the field of allergy our antibody product, MY006, for peanut allergy was derived from allergic patients and targets the major allergens thus preventing pathological IgE binding to peanut and anaphylaxis.